|View printer-friendly version|
G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitors Trilaciclib and G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Data on G1T38, a potential best-in-class oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications, were selected to be featured in the AACR 2018 Poster Discussion Session. Data on trilaciclib, a short-acting IV CDK4/6 inhibitor in development to preserve hematopoietic stem cells and enhance immune system function (myelopreservation) during chemotherapy, will also be presented.
Details on the presentations are as follows:
Title: The CDK4/6 inhibitor, G1T38, enhances response to targeted therapies in preclinical models of non-small cell lung cancer
Abstract Number: 1522
Session: Targeting the Cell Cycle: Mechanism and Therapy
Poster Number: 1
Date / Time / Location:
Title: Transient exposure to trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates and promotes a pro-inflammatory tumor microenvironment
Abstract Number: 1752
Session: Modifiers of the Tumor Microenvironment 2
Poster Number: 17
Date / Time / Location:
Additional information on the meeting can be found on the AACR website: www.aacr.org
About Trilaciclib (G1T28)
Trilaciclib is a short-acting CDK4/6 inhibitor in development to preserve hematopoietic stem cells and enhance immune system function (myelopreservation) during chemotherapy. Trilaciclib is administered intravenously prior to chemotherapy and has the potential to significantly improve treatment outcomes.
Trilaciclib is being evaluated in four randomized Phase 2 clinical trials. The company recently announced positive Phase 2a topline data showing myelopreservation benefits in newly diagnosed, treatment-naive small cell lung cancer (SCLC) patients (NCT02499770). There are three additional ongoing trilaciclib trials: a trial in previously treated SCLC patients (NCT02514447), a trial in patients with triple-negative breast cancer (NCT02978716), and a trial in combination with Tecentriq® and chemotherapy in SCLC patients (NCT03041311).
G1T38 is a potential best-in-class oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. Preclinical data presented at the
G1T38 is currently being evaluated in two Phase 1/2 clinical trials: a trial in combination with Faslodex® for people with estrogen receptor-positive, HER2-negative breast cancer (NCT02983071), and a trial in combination with Tagrisso® for people with EGFR-mutant non-small cell lung cancer (NCT03455829).
G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the therapeutic potential of trilaciclib, G1T38 and G1T48, and are based on G1 Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause G1 Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in G1 Therapeutics’ filings with the
Head of Investor Relations / Public Relations